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ABSTRACT 
What is known: There is increasing number of studies demonstrating the direct effect of 
the cannabinoid receptor 1 (CB1) antagonist / inverse agonist rimonabant on the opioid 
system; however they are mostly related to the mu opioid receptors (MOR). The 
dynorphin / kappa opioid receptor system is well known to mediate depression and 
anxiety like behavior. Clinical studies on chronic rimonabant administration have 
revealed that rimonabant leads to a very similar pathophysiology, suggesting a potential 
impact of rimonabant on the kappa opioid system. 
Objectives: Our objectives were to examine the possible interactions between 
rimonabant and KOR in the ligand-receptor and receptor-G-protein level to follow the 
direct effect of rimonabant on KOR mediated signaling in vitro by using KOR cell lines 
and forebrain tissues of mice lacking either CB1 cannabinoid or both CB1 and CB2 
cannabinoid receptors. Further on to better understand the clinical relevance of 
rimonabant on the KOR system we acutely treated mice with low dose of rimonabant and 
examined the KOR mediated G-protein activity and KOR protein expression levels of the 
forebrain tissues and also investigated the impact on depression- and anxiety-like 
behavior. 
Results: Rimonabant in Chinese hamster ovary (CHO) cell membrane fractions stably 
transfected with rat KOR (CHO-rKOR) inhibited the KOR agonist [3H] U69593 specific 
binding in the micromolar range in radioligand competition binding experiments and 
specifically reduced KOR basal activity at the lower micromolar concentrations in 
[35S]GTPγS binding assays. In addition, rimonabant significantly inhibited KOR 
stimulation in micromolar range during dynorphin (1-11)-induced [35S]GTPγS binding 
experiments performed in CHO-rKOR cell, CB1 single knockout (CB1K.O.) and CB1/CB2 
double knockout mouse forebrain membrane fractions. Our in vivo studies, by treating 
mice i.p. with a single dose of 0.1 mg/kg rimonabant, revealed that 24h following the 
administration dynorphin (1-11)-induced KOR G-protein activity and the KOR 
expression levels were significantly reduced both in wild type and CB1K.O. forebrain. 
Furthermore in elevated plus maze test the same treatment conditions showed an 
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anxiolytic like effect of rimonabant that was reversed by administration of 1 mg/kg KOR 
antagonist norbinaltorphimine.  
Conclusion: Rimonabant directly affects KOR function in micromolar concentrations in 
in vitro studies with a KOR specific inverse agonistic or antagonistic character. Our in 
vivo studies demonstrated that unlike upon chronic rimonabant administration which 
leads to undesired psychiatric dysfunctions, an acute low dose of rimonabant has an 
entirely opposite effect that is CB1 receptor independent. According to the information so 
far provided, this is the first report that links the impact of rimonabant on the KOR 
system at signaling, protein expression and behavioral level in such a pharmacological 
application. 
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ABBREVIATIONS 
CB1: type 1 cannabinoid receptor 
CB1/ CB2 K.O.: CB1/CB2 double knock-out 
CB2: type 2 cannabinoid receptor 
CB1 K.O.: CB1knock-out 
CHO: Chinese hamster ovary cell line 
CHO-rKOR: Chinese hamster ovary cell line overexpressing rat -opioid receptor 
DMSO: dimethyl sulfoxide 
DOR:-opioid receptor 
DPDPE: [D-Pen2,5]-enkephalin hydrate 
EGTA: ethyleneglycol-tetraacetic acid 
EPM: elevated plus maze test 
FST: forced swimming test 
GAPDH:  glycerine aldehyde phosphate dehydrogenase 
GDP: guanosine 5’-diphosphate 
GPCR: G-protein coupled receptor 
GTP: guanosin 5’-triphosphate 
GTPγS: Guanosine-5’-O-[γ-thio] triphosphate 
HRP: horseradish peroxidase 
i.p.: intraperitoneal 
KOR:-opioid receptor 
MOR: µ-opioid receptor 
Nor-BNI: norbinaltorphimine 
rim.: rimonabant 
S.E.M.: standard error of means 
TEM: Tris-HCl, EGTA, MgCl2 
Tris-HCl: tris-(hydroxymethyl)-aminomethane hydrochloride 
w.t.: wild type 
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1. INTRODUCTION 
 Rimonabant (Rinaldi-Carmona et al., 1994), which reduces endogenous 
cannabinoid receptor 1 activity (CB1), was the first appetite suppressant to be approved 
for medical use targeting CB1 receptors (Padwal and Majumdar, 2007). However because 
of its strong psychiatric side-effects, such as anxiety and depression, it was soon 
withdrawn from the market (Christensen et al., 2007). Several clinical (Christensen et al., 
2007; Moreira and Crippa, 2009) and after the withdrawn preclinical studies (Beyer et al., 
2010; Lockie et al., 2011) supported the psychiatric adverse effects of chronically 
administered rimonabant and frequently questioned its specificity at CB1 receptors (for 
review see Pertwee, 2010). 
From many aspects the opioid and the cannabinoid system have a lot in common. 
Similarly to the cannabinoid antagonists, opioid antagonists, such as naloxone, have an 
impact on food intake and body weight as well (Yeomans and Gray, 1997), though have 
not been successful in antiobesity therapies (de Zwaan and Mitchell, 1992). Also, the 
endogenous opioid system plays an important role in the regulation of behavior and 
emotions. Activation mediated by the μ- and δ-opioid receptors (MOR, DOR 
respectively) elevates mood (Filliol et al., 2000; Shippenberg et al., 2008), while 
signaling via the κ-opioid receptors (KOR) results in dysphoria and anxiety in humans 
(Pfeiffer et al., 1986; Wadenberg, 2003) and also in rodents (Bals-Kubik et al., 1993; 
Carlezon et al., 2009, 2006; Mague et al., 2003). KORs are widely expressed in brain 
areas which – in pathological conditions – are highly responsible for depression and 
anxiety disorders, including the hypothalamus, amygdala, locus coeruleus, nucleus 
accumbens (Beckstead et al., 1979; Schwarzer, 2009; Simon et al., 1979; Tanaka et al., 
2000). These regions involve the dopaminergic, the serotonergic and the noradrenergic 
systems (Berger et al., 2006; Hurd, 1996; Mansour et al., 1995; Schwarzer, 2009) that are 
the primary targets for standard antidepressant drugs (Frazer, 1997; Millan, 2004). Thus it 
is not surprising that several studies came out confirming that KOR antagonists have 
antidepressant- and anxiolytic-like effects (Knoll et al., 2007; Mague et al., 2003; 
McLaughlin et al., 2003; Millan, 2004; Newton et al., 2002; Schwarzer, 2009; Wittmann 
et al., 2009, for review see Carlezon et al., 2009). Similarly, the CB1 cannabinoid 
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receptors are widely expressed in brain areas that are directly coupled to process 
emotions, such as the prefrontal cortex, hippocampus, amygdala and hypothalamus (for 
review see Pertwee and Howlett, 2010).  
Opioids and cannabinoids share a lot of similarities at the receptor level as well. 
Both cannabinoid and opioid receptors belong to the G-protein coupled receptor (GPCR) 
superfamily. They predominantly activate Gi/o inhibitory proteins, which leads to the 
inhibition of adenylyl cyclase activity resulting a decreased presynaptic neurotransmitter 
release (Bruchas et al., 2010; Demuth and Molleman, 2006). There are also evidences for 
the interaction between the endocannabinoid system and KORs. For example, 
Δ-(9)tetrahydrocannabinol’s(THC) acute antinociceptive effects can be attenuated by 
KOR antagonist norbinaltorphimine (nor-BNI) (Smith et al., 1994). Other reports have 
highlighted the interaction between them at the level of nociception (Haller et al., 2008) 
or inflammation (Capasso et al., 2008). There are also data referring to the overlapping 
neuroanatomical localization and cross-talk between CB1 and the KOR: CB1 receptors 
and dynorphin are colocalized in striatal neurons (Hohmann and Herkenham, 2000) and 
also the KOR activity increases in the absence of CB1 receptors in mouse caudate 
putamen (Urigüen et al., 2005). 
 Recently there has been an increasing number of reports demonstrating the direct 
effect of rimonabant on opioid receptors (Cinar and Szücs, 2009; Fong et al., 2009; 
Kathmann et al., 2006), in the case of MOR and DOR, rimonabant seems to have an 
antagonistic character (Seely et al., 2012; Zádor et al., 2014, 2012). Lockie and co-
workers have shown that the endogenous mu opioid system is involved in modulating the 
metabolic effects of rimonabant whereas the endogenous kappa opioid system modulates 
the mood related properties of rimonabant after a high dose, chronic administration 
(Lockie et al., 2011). 
Stimulated by the observations that the mood related effects of rimonabant are 
linked to the κ-opioid system, we first investigated whether rimonabant can directly 
interact with the KOR at the ligand-receptor and receptor signaling level. In the next step, 
for our in vivo studies we applied an acute low dose to avoid the unspecificity of this 
compound that frequently occurs upon high dose, chronic administration and monitored 
the impact of rimonabant on KOR mediated G-protein activation, KOR protein 
 7 
expression rate and how all this contributes to depression- and anxiety-like behavior. 
Using Chinese hamster ovary cell lines (CHO) transfected with rat KOR (CHO-rKOR) as 
well as transgenic mouse lines lacking either CB1 or both CB1/CB2 cannabinoid 
receptors, we show that rimonabant cannabinoid receptor independently reduces KOR 
function at the level of ligand binding, receptor mediated G-protein activity and protein 
expression rate, which overall leads to altered anxiety like behavior. To the best of our 
knowledge, this is the first report linking the effect of rimonabant to the KOR system at 
signaling, protein expression and behavioral level in such a pharmacological application. 
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2. MATERIALS AND METHODS 
2.1. Chemicals 
Tris-HCl, EGTA, NaCl, MgCl2 x 6H2O, GDP, the GTP analogue GTPγS, the DOR 
specific agonist peptide DPDPE were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). The MOR agonist DAMGO was obtained from Bachem Holding AG (Bubendorf, 
Switzerland). The KOR agonist peptide dynorphin (1-11) was synthesized by the Isotope 
Laboratory of Biological Research Center (Szeged, Hungary), while the KOR antagonist 
nor-BNI was purchased from Tocris Bioscience (Bristol, UK). The opioid antagonist 
naloxone was kindly provided by the company Endo Laboratories DuPont de Nemours 
(Wilmington, DE, USA). SR141716 (rimonabant) was acquired from Santa Cruz (Dallas, 
Texas, USA). The radiolabelled GTP analogue, [35S]GTPγS (specific activity: >1000 
Ci/mmol) was purchased from the Isotope Institute Ltd. (Budapest, Hungary). The 
tritiated [Phenyl-3, 4-3H]-U69593 (3HU69593; specific activity: 30-60 Ci/mmol) was 
purchased from PerkinElmer (Boston, USA). The KOR internal rabbit polyclonal 
antibody was purchased from Invitrogen (Paisley, UK; catalogue number: 44302G). 
Rimonabant was dissolved in DMSO and similar to the other applied receptor ligands, 
was stored in 1 mM stock solution at -20C. 
2.2. Animals 
CB1 receptor knockout (CB1K.O.) mice and their controls were provided by Dr. 
György M. Nagy’s laboratory (Semmelweis University, Budapest) and were originally 
generated on CD1 background in Dr.Ledent‘s lab as described earlier (Ledent et al., 
1999). The CB1

/CB2 receptor double knockout mice (CB1

/CB2 K.O.; C57BL/6J 
background) were generated in Dr. Andreas Zimmer’s laboratory (University of Bonn, 
Germany) as described previously (Járai et al., 1999). The C57BL/6J wild type mice 
strains were bought from the local animal house of the Biological Research Center 
(Szeged, Hungary). All animals were two months old and the genders were half male and 
half female for the binding assays and Western blot studies, in case of behavior studies all 
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tested animals were male. All animals were housed at 21-24 ˚C under a 12:12 light: dark 
cycle and were provided with water and food ad libitum. All housing and experiences 
were conducted in accordance with the European Communities Council Directives 
(86/609/ECC) and the Hungarian Act for the Protection of Animals in Research 
(XXVIII.tv. 32.§). 
2.3. Animal treatments 
Rimonabant was dissolved in DMSO for [35S]GTPγS binding assays and Western 
blot studies. For behavioral studies rimonabant together with nor-BNI were dissolved in 
DMSO/ethanol/Tween80. Animals received a single intra peritoneal (i.p.) injection of 0.1 
or 1 mg/kg rimonabant, or 1 mg/kg nor-BNI, or the combination of 1 mg/kg nor-BNI and 
0.1 mg/kg rimonabant. Control groups received only vehicle. In the combined treatment 
nor-BNI was administered 30 min prior to rimonabant injection, so nor-BNI could 
occupy KOR before rimonabant is administered. 24h after the treatment animals were 
decapitated and their forebrains were prepared for binding assays, or were used for 
behavioral studies. 
2.4. Forebrain membrane preparations 
Forebrain membrane fractions from CB1 K.O. and CB1/ CB2 K.O. mice and their 
wild type controls were prepared as previously described (Benyhe et al., 1997) right up to 
the point where the membrane homogenate was prepared for the [35S]GTPγS binding 
assay. In this procedure the sucrose was removed by centrifugation (40 000 g, 20 min, 
4°C) and the pellet was suspended with ice-cold TEM buffer to obtain the appropriate 
protein content for the assay (~10 g/ml). 
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2.5. Cell culture and cell membrane preparations 
CHO-rKOR cells overexpressing rat KORs were provided by Dr. Zvi Vogel 
(Rehovot, Israel) and were characterized earlier (Avidor-Reiss et al., 1995). Briefly the 
cells were grown in Dulbecco’s modified Eagle’s medium and in α-minimum essential 
medium, respectively. Both media were supplemented with 10% fetal calf serum, 2 mM 
glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 25 mg/ml fungi zone and 0.5 
mg/ml geneticin and were kept in culture at 37˚C in a humidified atmosphere consisting 
of 5% CO2 and 95% air (Zádor et al., 2012). 
Cell membranes were prepared for competition binding experiments as we 
previously described (Zádor et al., 2012). For the [35S]GTPγS binding assays the 
membrane homogenate was prepared similarly except that the cells were homogenized in 
TEM buffer (50 mM Tris-HCl, 1 mM EGTA, and 5 mM MgCl2; pH 7.4). 
2.6. Radioligand competition binding assays 
In competition binding experiments we measure the inhibition of fix concentrations 
of specific radioligand binding in the presence of increasing concentrations of unlabeled 
competitor ligands. Radioligand competition binding assays were applied to investigate 
the direct binding affinity of rimonabant towards KOR. 
Aliquots of frozen CHO-rKOR membranes were first centrifuged (40000× g, 20 
min, 4˚C) to remove sucrose and the pellets were suspended in 50 mM Tris-HCl buffer 
(pH 7.4). Membranes were incubated with gentle shaking at 30˚C for 30 min in a final 
volume of 1 ml with 10-10 - 10-5 M concentration interval of unlabeled rimonabant 
together with 1 nM of 3HU69593. Total binding was measured in the presence of 
radioligand, in the absence of the displacer ligands. The non-specific binding was 
determined in the presence of 10 M unlabeled naloxone. The reaction was terminated by 
rapid filtration under vacuum (Brandel M24R Cell Harvester), and washed three times 
with 5 ml ice-cold 50 mM Tris-HCl (pH 7.4) buffer through Whatman GF/B glass fiber 
filters washed in 3% polyethylenimine for 60 min (to reduce non-specific binding of the 
radioligand). The radioactivity of the filters was detected in UltimaGoldTM MV aqueous 
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scintillation cocktail with Packard Tricarb 2300TR liquid scintillation counter. The 
competition binding assays were performed in duplicate and repeated at least three times. 
2.7. Functional [35S]GTPγS binding assays 
Functional [35S]GTPγS binding experiments monitor the nucleotide exchange 
process of the G-protein using a non-hydrolysable radiolabeled GTP analog, [
35S]GTPγS 
in the presence of increasing concentrations of the observed ligand. 
The assays were performed as previous described, with slight modifications (Sim et 
al., 1995; Traynor and Nahorski, 1995). Membrane fractions of CHO-rKOR, CB1 K.O., 
CB1/CB2 K.O.and wild type mouse forebrains were incubated in a final volume of 1 ml at 
30C for 60 min in a Tris-EGTA buffer (pH 7.4). The buffer was composed of 50 mM 
Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, containing 0.05 nM [
35S]GTPγS 
(20 MBq/0.05 cm3) and 30 M GDP. The incubation was performed together with the 
indicated concentrations of dynorphin (1-11), rimonabant, nor-BNI, DAMGO or DPDPE. 
Total binding (T) was measured in the absence of the ligands, non-specific binding (NS) 
was determined in the presence of 10 M unlabeled GTPγS and subtracted from total 
binding. The difference (TNS) represents basal activity. Bound and free [35S]GTPγS 
were separated by vacuum filtration through Whatman GF/B filters with Brandel M24R 
Cell harvester. Filters were washed three times with 5 ml ice-cold buffer (pH 7.4), and 
the radioactivity of the dried filters was detected in UltimaGoldTM MV scintillation 
cocktail with Packard Tricarb 2300TR liquid scintillation counter. The [35S]GTPγS 
binding experiments were performed in triplicates and repeated at least three times. 
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2.8. Western blot 
In Western blot studies wild type and CB1K.O. mice were used. Both CB1 K.O. 
animals and the corresponding controls received a single dose of vehicle or 0.1 mg/kg 
rimonabant i.p. and 24h after the injection the forebrains were prepared and the total 
protein was isolated as previously described (Lénárt et al., 2012). Western blot 
experiments were performed according to Lénárt and co-workers (Lénárt et al., 2012). 
The KOR antibody was diluted to 1:1000 and for loading control GAPDH was used. 
Signals were enhanced by Luminata Forte Western HRP Substrate (Millipore) and 
detected by a Nikon CCD 28 mm camera. Each group contained 5 animals and the 
experiments were repeated at least three times. 
2.9. Forced swimming test (FST) 
Forced swimming tests (FST) quantifies the depression-like behavior of the animal 
by monitoring the immobility period of the animal in water during the trial. The more the 
animal is immobile the more it shows depression-like behavior (Castagné et al., 2011). 
For the FST studies wild type male C57BL/6J mice were used. They received a single 
dose of vehicle or 0.1 mg/kg i.p. rimonabant. The tests were performed 24h following the 
treatments. The FST studies were conducted according to Gaszner and co-workers 
(Gaszner et al., 2012). Animals were placed individually in plastic cylinders (diameter 
11.5 cm, height 25 cm) containing 19 cm of water maintained at 24 ± 1°C temperature. 
Mice were unable to escape or touch the bottom of the cylinder. Each animal was forced 
to swim for 6 minutes, in which the duration of immobility was monitored manually in 
the last 4 minutes. Trials were recorded by digital camera (Nikon Coolpix L10) and 
analyzed later. Animals were placed 2 hours before the test to the measuring room and 
each animal was separated right before and right after the trial. At least eight animals per 
group were used and the tests were repeated at least three times, with at least 3 weeks 
interval in case of the same animal group. 
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2.10. Elevated plus maze test (EPM) 
Elevated plus maze tests (EPM) is used to examine the anxiety-like behavior of the 
animals by monitoring the fear of open spaces or heights of rodents (Walf and Frye, 
2007). Wild type male C57BL/6J mice were used, receiving a single i.p. dose of vehicle 
or rimonabant (at the dose of 0.1 or 1 mg/kg), or nor-BNI (at the dose of 1 mg/kg)or 1 
mg/kg nor-BNI in combination with 0.1 mg/kg rimonabant. The animals were tested 24h 
after the treatments. The experimental setup was accomplished according to Walf and 
Frye (Walf and Frye, 2007). Each animal was measured for 5 minutes and the tests were 
performed in a separate room. Animals were placed next to the measuring room 24h 
before the test. Trials were recorded by camera using the SMART Video Recording 
System (Panlab, Harvard Apparatus). Animals were separated before and after the trials. 
At least eight animals per group were used and the tests were repeated at least three times 
with at least one month interval in case of the same animal group. 
2.11. Data analysis 
Competition binding experiments and [35S]GTPγS binding assay data were 
presented and analyzed as previously described by our group (Zádor et al., 2014). In 
competition binding experiments the total specific binding and the minimum level of 
non-specific binding was defined as 100% and 0% respectively. In the [35S]GTPγS 
binding assays the basal activity was settled as 100%. Western blot results were analyzed 
with ImageJ image processing program. Each data was normalized to its own GAPDH 
data and then all data were normalized to the wild type control. FST results were video 
recorded and analyzed mechanically. The mouse was considered immobile when it 
stopped struggling, passively floated or performed small movements with only one of its 
legs to keep its head above the water. EPM test results were analyzed by the SMART 
Video Recording System, which monitored the time spent in the open arms and the 
distance traveled by the animals (for locomotor activity) among others.  
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2.12. Statistical analysis 
Statistical analyses were performed with GraphPad Prism 5.0. In case of two data 
sets unpaired t-test with two-tailed P value statistical analysis was used, while in case of 
three or more data sets One-way ANOVA with Bonferroni’s Multiple Comparison post 
hoc test was performed to determine the significance level. In case of the binding assays 
since both the competitor and stimulator ligands were presented in the logarithm form, 
the curve fitting program could only calculate S.E.M. for the logarithm form of IC50 
(logIC50) and EC50 (logEC50) values. At the same time their antilogarithm form has also 
been indicated on the figures for better understanding. Significance was accepted at the P 
< 0.05 level. 
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3. RESULTS 
3.1. Rimonabant directly inhibits KOR specific ligand binding in CHO-rKOR 
membrane fractions, but only at micromolar range 
Because rimonabant is able to bind with low affinity to other GPCR´s than the CB1 
receptors (Pertwee, 2010), including the MORs and DORs (Cinar and Szücs, 2009; 
Kathmann et al., 2006; Seely et al., 2012; Zádor et al., 2014, 2012) we first tested its 
direct binding ability to KORs. The investigations were carried out in competition 
binding experiments with a tritiated KOR specific agonist ligand, U69593 ([3H]U69593; 
~ 1 nM) in the presence of increasing concentrations of rimonabant (10-11- 10-5M). To 
insure a better receptor-ligand interaction, the binding experiments were prepared on 
membrane fractions of CHO cells overexpressing rat KOR (CHO-rKOR). 
Rimonabant was able to inhibit [3H]U69593 specific binding by 20% at 1 µM and 
by 60% at 10 µM (Fig. 1A) concentration with a 5.17 µM IC50 value (Fig. 1B). These 
results indicate that rimonabant can interact directly with KOR, but only with low 
affinity. 
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Fig. 1.  Competition of rimonabant for the binding sites of [3H]U69593 in 
CHO-rKOR membrane fractions. Membranes were incubated as described under 
section 2.6. (A) The figure represents the specifically bound fixed (~ 1 nM) 
concentrations of [3H]U69593 in percentage in the presence of increasing (10-10-10-5 M) 
concentrations of unlabeled rimonabant. “Total” on the X axis refers to the points which 
did not contain competitor ligands and also represents the total specific binding (=100%) 
in the presence of either radioligand. (B) The calculated logIC50 (binding affinity) of 
unlabeled rimonabant. Points and columns represent means ± S.E.M. for at least three 
experiments performed in duplicate. The antilogarithm form of logIC50 (IC50) value is 
presented in brackets. 
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3.2. Rimonabant has a direct impact on KOR G-protein activity in CHO-rKOR cell 
membranes 
Since rimonabant had a direct effect on KOR binding at higher concentrations, next 
we wanted to examine the impact of rimonabant on KOR mediated GPCR signaling. For 
this, again we used CHO-rKOR cell membrane preparations to avoid interactions with 
other opioid and cannabinoid receptors so to make certain that the observed effect of 
rimonabant on KOR G-protein is direct. The receptors G-protein activity was measured in 
functional [35S]GTPγS binding experiments. 
Firstly we verified that the applied CHO-rKOR cell lines do not express MOR and 
DORs. As expected, the DOR specific DPDPE and the MOR specific DAMGO did not 
increase [35S]GTPγS binding at 10 µM concentrations (Fig. 2A), thus we can confirm that 
the cell lines do not express neither MORs nor DORs. The neutral antagonistic and KOR 
mediated effect of nor-BNI was also confirmed, since1 µM concentrations of nor-BNI 
did not alter [35S]GTPγS specific binding significantly thus the KOR’s basal activity 
remained unaltered (Fig. 2A). Further on, it significantly decreased 
dynorphin (1-11)-enhanced [35S]GTPγS specific binding as well (Fig. 2A). 
In the next step we investigated the impact of rimonabant per se on KOR basal 
activity and we wanted to examine whether the possible effect can be reversed by nor-
BNI. In 0.5 µM concentrations rimonabant moderately decreased KOR basal activity 
which was indicated by the decreased [35S]GTPγS specific binding. This effect was 
reversed by nor-BNI (Fig. 2A). The reduction on KOR’s basal activity was more 
pronounced and also significant in the presence of higher concentrations (1 and 10 µM) 
of rimonabant (Fig. 2A). Interestingly 1 µM nor-BNI could only reverse the inhibitory 
effect of rimonabant when it was applied in 1 µM (Fig. 2A), which indicates that the 
inverse agonistic effect of rimonabant at 10 M concentrations is not KOR related. 
In the next step we activated the KOR with increasing concentrations 
(10-10-10-5M) of the KOR selective agonist dynorphin (1-11) and analyzed the 
KOR-mediated G-protein activity in the presence of 0.5, 1 and 10 µM of rimonabant. The 
experiments were again accomplished in functional [35S]GTPγS binding studies 
performed in CHO-rKOR cell membranes. Our results revealed that rimonabant dose 
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dependently inhibited the specific [35S]GTPγS binding of KOR-mediated G-protein 
during receptor activation (Fig. 2B), as a result the maximal efficacy (Emax) of the 
receptors G-protein also reduced dose dependently (Fig. 2C). The inhibition was the most 
elicit at 1 and 10 µM concentrations (Fig. 2C). The potency (EC50) of the activator ligand 
was also dose-dependently decreased (data not shown, control: 32.6 nM, 
0.5 µM rim.: 42.9 nM, 1µM rim.: 75.3 nM, 10 µM rim.: 138.7 nM), at 10 µM 
concentrations the reduction was significant (One-way ANOVA, Bonferroni’s Multiple 
Comparison post hoc test, P<0.05). These results correspond with our competition 
binding experiments (see section 3.1, Fig.1A and B). 
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Fig. 2.  The effect of rimonabant on KOR G-protein activity in ligand-
modulated [35S]GTPγS binding assays, in CHO-rKOR cell membranes. Membranes 
were incubated according to section 2.7. (A) The figure represents the specifically bound 
[35S]GTPγS in percentage in the presence of the indicated ligand concentrations alone or 
together with 1 μM nor-BNI. * indicates the significant alterations in specifically bound 
[35S]GTPγS, compared to basal activity (One-way ANOVA, Bonferroni’s Multiple 
Comparison post hoc test; 10 M dyn. (1-11): P<0.001, 1 M rim.: P<0.05, 10 M rim.: 
P<0.001). # indicates the significant reduction in the specifically bound [35S]GTPγS 
during dynorphin (1-11) stimulation in the presence of nor-BNI compared to dynorphin 
(1-11) alone (One-way ANOVA, Bonferroni’s Multiple Comparison post hoc test; 
P<0.001). The basal activity (=100%) is indicated by the line. (B) The figure indicates the 
specifically bound [35S]GTPγS in percentage in the presence of increasing concentrations 
(10-10-10-5M) of dynorphin (1-11) in the absence or presence of the indicated rimonabant 
concentrations. “Basal” on the X axis refers to the points which did not contain dynorphin 
(1-11). (C) The calculated Emax (maximal efficacy) value of KOR G-protein over basal 
activity (100%) after agonist stimulation in the presence or absence of the indicated 
rimonabant concentrations. Points and columns represent means ± S.E.M. for at least 
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three experiments performed in triplicate. * indicates the significant reduction in Emax 
values in the presence of rimonabant compared to dynorphin (1-11) alone (One-way 
ANOVA, Bonferroni’s Multiple Comparison post hoc test; 1 M rim.: P<0.05; 10 M 
rim.: P<0.001). 
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3.3. Rimonabant inhibited KOR G-protein activity CB1 and CB2 cannabinoid receptor 
independently in dynorphin (1-11)-stimulated [35S]GTPγS binding performed in 
mouse forebrain membranes 
In the previous set of experiments on KOR-CHO cell lines we have seen that 
rimonabant was capable of altering KOR mediated G-protein activity alone, or via 
inhibiting dynorphin stimulated activation. We have also shown that this is likely due to 
the specific binding ability of rimonabant to KOR at lower micromolar concentrations as 
it was able to partially displace [3H]U69593. Thus, if we hypothesize that rimonabant has 
an influence on KOR mediated signaling at the lower micromolar concentrations the role 
of other receptors that are in a very close proximity of KOR - such as the CB1 
cannabinoid receptor - should be considered. Therefore, we used CB1 single knockout 
mice to follow the role of CB1 receptors in rimonabant altered dynorphin (1-11) 
stimulated functional [35S]GTPγS binding. Furthermore, because there are increasing 
numbers of publications showing the neuronal presence of cannabinoid receptor type 2 
(CB2) in the brain moreover their interaction with opioid receptors (Páldyová et al., 
2008), we looked at the effect of rimonabant on dynorphin (1-11) stimulated G-protein 
activity in CB1/CB2 double knockout mice as well. For all our experiments on mouse 
brain membrane preparations only the forebrain part was used, in which the KORs, and 
the CB1,CB2 receptors are in eligible amount (Lever, 2007; Sim and Childers, 1997; 
Svízenská et al., 2008) and importantly this brain region is mainly responsible for 
emotion and anxiety formation at the central (eg. amygdala) and highest cortical levels 
(Beckstead et al., 1979; Schwarzer, 2009; Simon et al., 1979; Tanaka et al., 2000). 
In wild type forebrain membranes the inhibitory effect of rimonabant upon 
KOR-mediated G-protein maximal efficacy occurred as well in 1 μM concentrations 
during dynorphin (1-11)-stimulated KOR activation (Fig. 3A-C). However the potency of 
the activator ligand was unaffected (data not shown). Interestingly similar results were 
observed in CB1 K.O. and CB1/CB2 K.O. mouse forebrain membranes (Fig. 3A-C), 
additionally the lack of either cannabinoid receptors did not alter the 
dynorphin (1-11)-stimulated KOR G-protein activity significantly (Fig. 3A-C). 
Taken together our in vitro data on the influence of rimonabant on KOR, we 
demonstrated in competition binding experiments that rimonabant was able to displace 
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the KOR specific ligand but only at micromolar concentrations, and with a high IC50 
value. Rimonabant also effected KOR signaling: the compound decreased the receptors 
G-protein activity in CHO cell membranes over expressed with human KORs and in 
mouse forebrains CB1 and CB2 receptor independently. 
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igure 3 The effect of rimonabant on KOR G-protein activity in dynorphin (1-
11)-stimulated [35S]GTPγS binding assays, in wild type and in CB1 K.O. (A and B) or 
CB1/CB2 double K.O. (C and D) mouse forebrain membranes. Forebrain membranes 
were incubated as described under section 2.7(A and C). The figures represents the 
specifically bound [35S]GTPγS in percentage in the presence of increasing concentrations 
(10-10-10-4M) of dynorphin (1-11) in the absence or presence of 1 μM rimonabant. 
“Basal” on the X axis refers to the points which did not contain dynorphin (1-11) (B and 
D). The figures represent the calculated Emax (maximal efficacy) value of KOR G-protein 
activity after dynorphin (1-11) stimulation in the presence or absence of 1 μM 
rimonabant. Points and columns represent means ± S.E.M. for at least three experiments 
performed in triplicate. * indicates the significant reduction in Emax values in the presence 
of rimonabant compared to dynorphin (1-11) alone (unpaired t-test, two-tailed P value; 
P<0.05).  
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3.4. Acute treatment with low dose of rimonabant inhibits dynorphin (1-11)-stimulated 
[35S]GTPγS binding in wild type and CB1 K.O. mouse forebrain membranes 
 Our in vitro studies on CHO-rKOR cell lines as well as on forebrain membrane 
preparations have shown the inhibitory action of rimonabant on KOR mediated G protein 
activity that was CB1 and CB2 receptor independent. Next, we wanted to investigate the 
impact of rimonabant on KOR activity upon in vivo administration. There are many 
publications representing the unspecific effect of rimonabant upon chronic administration 
(Beyer et al., 2010; Christensen et al., 2007) moreover, relating it to kappa opioid 
receptor mediated mood behavior (Lockie et al., 2011). However, the effect of an acute, 
low dosage of rimonabant on KOR system is not well established. Therefore, we 
administered a single 0.1 mg/kg dose of rimonabant intra peritoneally (i.p.) into CB1 K.O. 
mice and into their corresponding controls. 24h after the treatment the animals were 
sacrificed and the KOR mediated G-protein activity was measured in functional 
[35S]GTPγS binding experiments on the forebrain region.  
 Rimonabant was able to significantly decrease the maximal efficacy of dynorphin 
(1-11)-stimulated KOR mediated G-protein activation in CB1 KO mouse forebrain 
membranes and the observed inhibition was comparable with the corresponding controls 
(Fig. 4), yet again indicating a CB1 receptor independent effect. The potency of 
dynorphin (1-11) remained unaltered (data not shown). 
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Figure 4 The acute low dose effect of rimonabant on KOR G-protein activity in 
dynorphin (1-11)-stimulated [35S]GTPγS binding assays, in wild type and in CB1 
K.O. mouse forebrain membranes. Animal treatments were accomplished as described 
under section 2.3 and the forebrain membranes were incubated as discussed in section 
2.7. (A) The figure represents the specifically bound [35S]GTPγS in percentage in the 
presence of increasing concentrations (10-9-10-5M) of dynorphin (1-11) after acute low 
dose rimonabant treatment. “Basal” on the X axis refers to the points which did not 
contain dynorphin (1-11). (B) The figure represents the calculated Emax (maximal 
efficacy) value of KOR G-protein activity during dynorphin (1-11) stimulation after acute 
rimonabant. Points and columns represent means ± S.E.M. for at least three experiments 
performed in triplicate. * indicates the significant reduction in Emax values after acute low 
dose rimonabant treatment compared to vehicle (unpaired t-test, two-tailed P value; 
P<0.05).  
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3.5. Acute effect of low dose rimonabant decreases KOR protein expression levels in 
both wild type and CB1 K.O. mouse forebrains in Western blot studies 
 In the previous set of experiments we have shown that a single i.p. injection of 
0.1mg/kg rimonabant is able to alter KOR mediated intracellular signaling in a CB1 
receptor independent manner. In the next step we addressed to look at the effect of 
rimonabant on other possible levels, therefore we examined at the KOR protein 
expression 24h after rimonabant treatment. 
We have seen that 0.1 mg/kg i.p. rimonabant treatment slightly, but significantly 
decreased relative KOR protein expression rate in wild type and also in CB1 K.O. mouse 
forebrains compared to vehicle treated mice (Fig. 5B). These results indicate a CB1 
receptor independent inhibition of a single i.p. dose of rimonabant on KOR protein 
expression level. However since the reduction was minor, the blot did not reflect the 
quantificational results (Fig. 5A). 
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Figure 5 The effect of acute low dose rimonabant treatment on KOR protein 
expression levels in Western blot studies in wild type and in CB1 K.O. mouse 
forebrains. Animal treatments and Western blot experiments were accomplished as 
described under section 2.3 and 2.8 respectively. (A) The figure represents the detected 
KOR expression levels in control and after rimonabant treatment in wild type and in CB1 
K.O. mouse forebrains. The expression level of the housekeeping gene GAPDH is also 
indicated as an internal for control. (B) The figure represents the quantification of 
blotting experiments. Columns represent means ± S.E.M. for at least three experiments 
performed in four parallels. * indicates significant reduction in relative KOR protein 
expression rate after acute low dose of rimonabant compared to vehicle (unpaired t-test, 
two-tailed P value; P<0.05). 
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3.6. Rimonabant modulates anxiety-like but not depression-like behavior, when 
administered acutely at 0.1 mg/kg dose, which can be reversed by KOR antagonist 
 As the KOR system is known to have a major impact on mediating depression and 
anxiety (Bals-Kubik et al., 1993; Carlezon et al., 2009, 2006; Mague et al., 2003; Pfeiffer 
et al., 1986; Wadenberg, 2003) our final goal was to test whether all the inhibitory actions 
provoked by rimonabant at the KOR signaling and KOR protein expression level have 
any consequences at behavioral level. We have performed elevated plus maze test (EPM) 
(Walf and Frye, 2007), a widely accepted behavioral test for anxiety-like behavior, and 
forced swim test (FST) (Castagné et al., 2011), a conventional test for depression-like 
behavior. 
In the EPM studies we first tested the anxiolytic effect of nor-BNI, a KOR 
antagonist. We have seen that mice treated with 1mg/kg nor-BNI spent more time in open 
space (Fig. 6A) when compared to the vehicle treated animals which goes along with 
previous reports (Schwarzer, 2009). Upon a single dose of 0.1 mg/kg rimonabant the 
mice spent also more time in open space, showing an anxiolytic-like behavior (Fig 6A). 
The extent of this effect is not dose dependent as mice treated with 1mg/kg rimonabant 
show comparable results (Fig 6A). Interestingly, the anxiolytic effect of rimonabant could 
be reversed by pretreatment with nor-BNI, showing that KORs are involved in this effect. 
Finally, the mice from the different groups showed comparable values in locomotor 
activity (data not shown).  
Acutely injected rimonabant at the dose of 0.1 mg/kg did not cause any significant 
change in depression-like behavior in FST studies (Fig. 6B) as the immobility parameters 
were similar to the vehicle treated animals. This result indicates that rimonabant does not 
affect the depression like behavior under these conditions. 
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Figure 6 The effect of acute low dose rimonabant treatment on depressive- and 
anxiety-like behavior in wild type mice. Animal treatments were conducted as 
described under section 2.3, while EPM and FST behavioral tests were performed as 
described in section 2.9 and 2.10 respectively. (A) Elevated plus maze test results 
representing the time spent in open space compared to the total test duration time, which 
quantifies the anxiety-like behavior of the animals. Combined treatment refers to the co-
injection of 1 mg/kg nor-BNI and 0.1 mg/kg rimonabant. * indicates the significant 
enhancement in the values compared to vehicle (One-way ANOVA, Bonferroni’s 
Multiple Comparison post hoc test; 0.1 mg/kg rim.: P<0.01, 1 mg/kg nor-BNI: P<0.05; 
1 mg/kg rim.: P<0.05) while # represents the significant reduction of the combined 
treatment values compared to 0.1 mg/kg rimonabant and 1 mg/kg nor-BNI alone (One-
way ANOVA, Bonferroni’s Multiple Comparison post hoc test; P<0.01). (B) Forced-
swimming test results representing the immobility time in percentage compared to the 
total test duration time. This type of experiment quantifies the depressive-like behavior of 
the animals. Columns represent means ± S.E.M. for at least three experiments performed 
with at least 8 animals per group in all behavioral tests. 
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4. DISCUSSION 
Since the development of the CB1 receptor antagonist/inverse agonist rimonabant, 
there have been a growing number of studies describing its non-CB1 related actions (Fong 
et al., 2009; Le Foll and Goldberg, 2005; Pertwee, 2010). The opioid system is one of the 
most likely interactional partner of rimonabant (Fong et al., 2009; Kathmann et al., 2006; 
Le Foll and Goldberg, 2005; Pertwee, 2010), though with evidences mostly related to the 
MOR system (Cinar and Szücs, 2009; Kathmann et al., 2006; Seely et al., 2012; Zádor et 
al., 2012). Because the KORs have a major role on mediating anxiety- and depression-
like behavior and rimonabant is also known for inducing mood alterations, our study 
focused on to better understand the background of the possible connection between these 
findings. After investigating the direct impact of rimonabant in vitro in CHO-rKOR cell 
lines and in forebrain membrane preparations, we applied an acute low dose of 
rimonabant and followed the alterations in KOR signaling and KOR protein expression 
level in the forebrain, which to the best of our knowledge was never reported before. 
Finally, but most interestingly we revealed these consequences at the behavioral level. 
For our studies we used CHO-rKOR cells lines and either CB1 single knockout or 
CB1/CB2 double knockout mice to better understand the involvement of these receptors in 
the observed effects. 
We first investigated the direct binding affinity of rimonabant to KORs in 
competition binding experiments in CHO-rKOR membrane fractions. According to these 
studies, rimonabant directly inhibited KOR radioligand binding, but only in the 
micromolar concentrations. These findings correspond well with previous reports on 
other opioid receptors in similar experimental conditions (Cinar and Szücs, 2009; Fong et 
al., 2009; Kathmann et al., 2006; Seely et al., 2012; Zádor et al., 2012, 2014). 
Because rimonabant affected KOR binding in the micromolar range, we examined 
whether rimonabant can effect KOR mediated G-protein basal activity and KOR 
activation in similar concentrations. These studies were accomplished in [35S]GTPγS 
binding assays using CHO-rKOR cell membranes. Our results revealed that rimonabant 
shows both an inverse agonistic as well as an antagonistic character at this level. 
Rimonabant significantly inhibited KOR mediated G-protein basal activity, indicating an 
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inverse agonistic character. This effect was reversed by the KOR antagonist nor-BNI at 
lower (0.5 and 1 M) micromolar concentrations, but not at higher micromolar range (10 
M), indicating rimonabant´s KOR specificity only at lower micromolar range. Therefore 
10 M or higher concentration of rimonabant might be considered as unspecific, which 
correlates with previous reports on MOR and DOR transfected CHO cell lines (Cinar and 
Szücs, 2009; Seely et al., 2012; Zádor et al., 2014) or with publications showing a 
non-CB1 receptor related inverse agonistic effect of rimonabant at these concentrations 
(Breivogel et al., 2001; MacLennan et al., 1998). We have also shown that in 
dynorphin (1-11)-stimulated G-protein activity measurements performed in CHO-rKOR 
cell membranes, rimonabant could significantly decrease maximal G-protein activity at 1 
M and 10 M concentrations and the potency of the activator ligand in 10 M 
concentrations. The inhibitory effect of rimonabant upon KOR activation can be due to 
either an inverse agonistic or antagonistic character, that might be partially unspecific at a 
higher, 10 M concentrations. The reduced stimulator ligand potency confirms previous 
data from U69593-stimulated [35S]GTPγS binding experiments performed in CHO-rKOR 
cell membranes (Walentiny et al., 2010). Additionally, similar results were observed 
previously by our group in experiments performed with MOR (Zádor et al., 2012) and 
DOR (Zádor et al., 2014).  
In nature, GPCRs are well known to dimerize with each other or with distant 
families forming homo-, heterodimers or oligomers (Birdsall, 2010; Fonseca and 
Lambert, 2009; González-Maeso, 2011), moreover they are able to influence other 
GPCR´s activity without having a direct interaction (González-Maeso, 2011; Hamm, 
1998; Hur and Kim, 2002; Jordan and Devi, 1999; Selbie and Hill, 1998). The CB1 
cannabinoid receptor, which is the main receptor that mediates the effects of rimonabant, 
is the most widely expressed GPCR in the brain (Herkenham et al., 1991; Howlett et al., 
1990) and shows overlapping expression with KOR at the regions of our interest 
(Hohmann and Herkenham, 2000; Lever, 2007; Mansour et al., 1995; Marsicano and 
Lutz, 1999; Sim and Childers, 1997; Svízenská et al., 2008). Recently, the CB2 
cannabinoid receptor has been also shown to have neuronal expression in different brain 
regions (Gong et al., 2006; Herkenham et al., 1991; Pertwee and Howlett, 2010; 
Svízenská et al., 2008; Van Sickle et al., 2005) and it has been reported to interact with 
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the opioid receptor system (Páldy et al., 2008; Páldyová et al., 2008). Because these 
receptors are expressed in the brain, further KORs and CB1 receptors could be either 
somatodendrically located within a neuron or could be present in the axon terminals 
(Arvidsson et al., 1995; Thibault et al., 2013), the direct impact on each other´s activity 
should be considered. Therefore, to better understand if the two cannabinoid receptors are 
involved in the effects of rimonabant on KOR system, we used genetically modified mice 
lacking either CB1 or both CB1/CB2 cannabinoid receptors and followed the impact of 
rimonabant on KOR signaling. Functional [35S]GTPγS binding assay revealed that 
rimonabant at 1 M concentration was able to inhibit dynorphin (1-11)-stimulated 
[35S]GTPγS binding in mouse forebrain membrane preparations. This effect was CB1 and 
CB2 receptor independent as both the knockouts showed comparable results with their 
corresponding controls. Similar results were observed by our previous studies regarding 
to MOR (Zádor et al., 2012) and DOR (Zádor et al., 2014). 
Evidences showing a cross-talk between the endocannabinoid and the endogenous 
opioid system have been widely published (for review see Cota et al., 2006; Manzanares 
et al., 2005), even at the level of KOR (Gerald et al., 2006; Ghozland et al., 2002; Lockie 
et al., 2011; Steiner et al., 1999; Urigüen et al., 2005; Walentiny et al., 2010). 
Rimonabant and the opioid system is known to have a bidirectional interaction as well, 
for example it can directly interact with MORs and DORs (Cinar and Szücs, 2009; Fong 
et al., 2009; Kathmann et al., 2006; Seely et al., 2012; Zádor et al., 2014, 2012). Recently, 
it has been revealed that the -opioid system is involved in metabolic effects, whereas the 
-opioid system affects the mood related properties of rimonabant at higher, repeated 
administration (Lockie et al., 2011). However, when choosing the right dose of 
rimonabant for in vivo administration one should be very careful, as upon a chronic 
and/or high micromolar dose application its non-CB1 mediated effects will probably 
occur(Le Foll and Goldberg, 2005; Pertwee, 2010). Therefore, for our in vivo studies we 
choose a lower, and not yet reported dose of 0.1 mg/kg, since so far the vast majority of 
the demonstrated interactions of rimonabant with the opioid system were described with 
at least ten times higher dosage (Beyer et al., 2010; De Vries et al., 2003; Le Foll and 
Goldberg, 2005; Lockie et al., 2011). We used CB1 knockout mice to understand the 
impact of the CB1 receptors in the observed effects and we first followed the changes in 
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KOR signaling and KOR protein expression level 24h after rimonabant administration in 
the forebrain. Similarly to that of seen in the in vitro studies, rimonabant showed an 
inhibitory effect on dynorphin (1-11)-stimulated KOR G-protein activity in [35S]GTPγS 
binding assays which was yet again comparable in CB1 K.O. and their controls, 
indicating a CB1 receptor independent action. These results correspond with previously 
described G-protein activity measurements accomplished on MOR in similar 
experimental conditions (Zádor et al., 2012). However, it’s worth to note that the 
mechanisms behind the acute in vivo effects of rimonabant on KOR G-protein activity 
might be entirely different and more complex from that of seen in vitro. One possible 
explanation could be that the very low dose systematic administration of rimonabant 
reduces the available KOR receptors in the forebrain; therefore the activator ligand 
activates fewer receptors in the system. Thus, we have followed the changes of KOR 
protein expression levels in Western blot studies. We have seen a slight, but significantly 
decrease of the KOR protein expression which might lead, or at least partially contribute 
to the observed effects on KOR signaling.  
The anxiety modulating effects of rimonabant are well known, though the results 
on this topic are rather conflicting (Beyer et al., 2010; Lee et al., 2009; Lockie et al., 
2011; Navarro et al., 1997; Rodgers et al., 2003). Rimonabant, as an antiobesity drug was 
withdrawn from the market because of a significant drug-related risk of serious 
psychiatric disorders including anxiety and depression. The undesirable effects occurred 
after chronic treatment according to clinical (Christensen et al., 2007; Moreira and 
Crippa, 2009) and preclinical studies (Beyer et al., 2010). However there are evidences 
showing that acutely administered low dose (1-3 mg/kg) of rimonabant can have 
anxiolytic effects on rodents in EPM studies (Haller et al., 2002; Rodgers et al., 2003, 
Arévalo et al., 2001,Navarro et al., 1997) and can also reduce depression in FST studies 
(Tzavara et al., 2003). According to Lee and co-workers 10 mg/kg per os single 
rimonabant treatment also reduced immobility in FST studies to the level of imipramine, 
a standard antidepressant (Lee et al., 2009). 
At the same time, there is little known what players might be participating in the 
psychiatric effects upon acute administration. Stimulated by the observations that the 
mood related effects of rimonabant are linked to the KOR system (Lockie et al., 2011), 
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but trying to avoid the unspecificity of this compound, we have conducted behavior 
studies to examine the depression-and anxiety-like behavior of wild type mice after the 
same rimonabant treatment conditions applied in our previous studies. Accordingly 0.1 
mg/kg rimonabant provoked an anxiolytic effect in EPM studies 24h following the i.p. 
treatment. Similar results were observed by Haller and co-workers (Haller et al., 2002), 
but with higher dosage (3 mg/kg). Moreover this effect was inhibited by the KOR 
antagonist nor-BNI, indicating the KOR specificity of rimonabant in this action. 
Rimonabant showed CB1 receptor independent inhibitory actions both in our in 
vitro and in vivo studies. Importantly the in vitro effects of the compound in micromolar 
concentrations directly involved the KORs, more likely in an inverse agonistic or 
antagonistic manner. Similar conclusion can be made according to the EPM studies, since 
it had anxiolytic effect through KOR and also it is known that KOR antagonists have 
anxiolytic effects (for review see Carlezon et al., 2009). Additionally, the low dose acute 
treatment reduced KOR protein expression rate, which may result the diminished KOR 
mediated G-protein activity after the treatment. However this effect of rimonabant may 
also be indirect, since GPCRs have very complex signaling systems (Oldham and Hamm, 
2008), namely they can cross-regulate each other’s signaling pathways, communicate 
with one and other capable of altering each other’s physiological responses(González-
Maeso, 2011; Hamm, 1998; Hur and Kim, 2002; Jordan and Devi, 1999; Selbie and Hill, 
1998). 
Despite of the knowledge that rimonabant shows unspecific properties after high 
dose or chronic administration, here we report that even an acute, low application leads to 
a CB1 receptor independent action, namely via effecting the KOR signaling system at 
different levels. This impact has direct consequences at the behavioral level, but 
importantly the anxiolytic effect is entirely opposite to that of observed after repeated 
application. Further, this study goes along with our previous (Zádor et al., 2012; 2014) 
and other findings (Cinar and Szücs, 2009; Kathmann et al., 2006; Lockie et al., 2011; 
Seely et al., 2012) about the capability of rimonabant to modulate all the three opioid 
receptor´s function at the signaling level at various concentrations. Thus, the possible 
players mediating the effect of rimonabant are far more complex than it was originally 
thought.  
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